文献速递免疫规划慢病防控与筛查

南非HIV阳性与HIV阴性女性单剂9价HPV疫苗有效性的模型估算

Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
PubMed 文献 · Vaccine · 2018-06-08

研究将动态HIV传播模型扩展至包含HPV获得与宫颈癌发病机制,模拟南非夸祖鲁-纳塔尔省青春期前女性单剂9价HPV疫苗接种的效果。在90%覆盖率、80%终身疫苗效力假设下,接种70年后普通女性人群宫颈癌发病率预计降低74%、死亡率降低71%;HIV阴性、HIV阳性及HIV阳性接受抗逆转录病毒治疗(ART)女性的年龄标化发病率和死亡率下降幅度相当。若假设疫苗保护在接种后10、15、20年减弱,健康获益则降低。

要点

  • 单剂9价HPV疫苗在90%覆盖率、80%终身效力下,预计70年后普通女性宫颈癌发病率降低74%、死亡率降低71%。
  • HIV阴性、HIV阳性及HIV阳性接受ART女性的年龄标化宫颈癌发病率和死亡率下降幅度相当。
  • 若假设疫苗保护在10、15、20年后减弱,健康获益降低。

核心结论

  • 单剂9价HPV疫苗接种预计可在南非及类似高HIV流行地区大幅减少宫颈癌负担。
  • 按HIV状态、CD4计数和ART状态分层的所有女性亚组中健康获益相当。

研究设计与样本

  • 将动态HIV传播模型扩展至包含HPV获得和宫颈癌发病机制,模拟南非夸祖鲁-纳塔尔省青春期前女性单剂9价HPV疫苗接种。
  • 分别报告HIV阳性女性(按HIV治疗和CD4计数分层)与HIV阴性女性的HPV疫苗接种健康影响。

主要发现

  • 在90%女性9岁覆盖率、80%终身疫苗效力假设下,单剂HPV疫苗接种预计在接种程序开始后70年使普通女性人群宫颈癌发病率降低74%、死亡率降低71%。
  • HIV阴性女性、HIV阳性女性及HIV阳性接受ART女性的年龄标化宫颈癌发病率和死亡率下降幅度相当。
  • 若假设疫苗保护在接种后10、15、20年减弱,健康获益降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Women in sub-Saharan Africa have high dual burden of HPV and HIV infections, which can interact to increase cervical cancer (CC) risk. The 9-valent HPV (9vHPV) vaccine has high demonstrated effectiveness against HPV types causing 90% of CC. Additionally, one dose of the 9vHPV vaccine has the potential to achieve greater coverage at lower costs than a two-dose schedule. However, the potential impact of single-dose 9vHPV vaccine accounting for HPV-HIV interactions has not been estimated. METHODS: We adapted a dynamic HIV transmission model to include HPV acquisition and CC pathogenesis and projected the impact of a single dose 9vHPV preadolescent vaccination in KwaZulu-Natal, South Africa. We report health impacts of HPV vaccination separately for HIV-positive women stratified by HIV treatment and CD4 count and HIV-negative women. RESULTS: At 90% coverage of females age 9 years with 80% lifelong vaccine efficacy, single dose HPV vaccination was projected to reduce CC incidence by 74% and mortality by 71% in the general female population at 70 years after the start of the vaccination program. Age-standardized CC incidence and mortality reductions were comparable among HIV-negative women, HIV-positive women, and HIV-positive women on ART. Health benefits were reduced when assuming waning protection at 10, 15 and 20 years after vaccination. DISCUSSION: Single dose 9vHPV vaccination is projected to avert substantial CC burden in South Africa and similar high HIV prevalence settings. Health benefits were comparable across all female subpopulations stratified by HIV status, CD4 count, and ART status.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Tan N, Sharma M, Winer R, et al. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa. Vaccine. 2018. PMID: 29891348. doi:10.1016/j.vaccine.2018.02.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。